Noticias

Premiada con 50.000 euros una investigación para mejorar la detección de la ELA, liderada por Ivonne Jericó y Jacinto López de Navarrabiomed - FMS

Mónica Povedano e Ivonne Jericó.
Author
Navarrabiomed


•    La Fundación hna ha reconocido también un proyecto del Instituto de Investigación Biomédica de Bellvitge (IDIBELL)



La cuarta edición del Premio Investigación Científica de Salud de Fundación hna ha reconocido recientemente en Madrid dos estudios orientados a la detección de nuevos biomarcadores biomarcadores para la detección temprana de la Esclerosis Lateral Amiotrófica (ELA); uno de ellos desarrollado en Navarrabiomed por Ivonne Jericó y Jacinto López

Durante la ceremonia de clausura, celebrada el 30 de mayo, se entregó el primer galardón, dotado con 100.000 euros, al proyecto “Caracterización de las vías moleculares subyacentes en el espectro patológico ELA-DFT en base a la expresión fenotípica: nuevos biomarcadores”, que lidera la investigadora principal Mónica Povedano, del Instituto de Investigación Biomédica de Bellvitge (IDIBELL). El segundo premio, dotado con 50.000 euros, fue para “Identificación y caracterización del sustrato de la enzima quitotriosidasa-1 (Chit1) en tejido neurológico post mortem en ELA”, que dirige Ivonne Jericó. 

La investigación de la neuróloga del Hospital Universitario de Navarra e investigadora en Navarrabiomed, Ivonne Jericó, se realizará en estrecha colaboración con la Unidad de Cristalografía de Proteínas e Inmunología Estructural, dirigida por Jacinto López, que se encargará de las actividades experimentales que son objetivo de este proyecto.
 

Más información Fundación hna

La edición 2024 del Premio Investigación Científica de Salud de Fundación hna había recibido 10 candidaturas de estudios sobre biomarcadores diagnóstico de ELA. Los biomarcadores son valores que pueden medirse, y con ello ser utilizadas como indicadores de un proceso biológico (normal, patogénico o de respuesta a un tratamiento). 

Esta es la segunda ocasión en que el Premio de Investigación Científica de Salud de Fundación hna se centra en la ELA, enfermedad que ya se abordó en la primera convocatoria de los galardones, lanzada en 2020 y donde es necesaria una continua investigación para conseguir combatirla. 

Fundación hna es una entidad sin ánimo de lucro, constituida en 2018 por la Hermandad Nacional de Arquitectos, Arquitectos Técnicos y Químicos, Mutualidad de Previsión Social. La misión de la fundación es la promoción de proyectos de investigación en medicina y salud en beneficio de los pacientes y de la ciencia, impulsar la profesión de la Arquitectura, la Arquitectura Técnica y la Química con especial énfasis en el colectivo de los futuros profesionales, así como contribuir a la mejora de la calidad de vida de los mutualistas de hna.

Categoría
Galería de imágenes
Mónica Povedano e Ivonne Jericó.
Download Flecha que indica descarga
Documentación
Vídeo

Resolución de las Ayudas para la intensificación de personal F.E.A. en Anatomía Patológica y en Neurología para el Biobanco de Navarrabiomed

Ayudas Biobanco
Author
Navarrabiomed

La Unidad de Gestión de Navarrabiomed - Fundación Miguel Servet ha difundido el martes, 4 de junio, la propuesta de adjudicación y adjudicación de las Ayudas para la intensificación de personal F.E.A. en Anatomía Patológica y de Neurología para el Biobanco de Navarrabiomed. Las personas beneficiarias deberán comunicar a la Unidad de Gestión de Navarrabiomed en el plazo máximo de 7 días naturales desde la presente notificación la aceptación o renuncia de la correspondiente ayuda.

A continuación, se facilita la documentación de ambas ayudas:

Categoría
Documentación
04/06/2024
Propuesta de adjudicación y adjudicación "Ayuda para la intensificación de personal F.E.A en Anatomía Patológica para el Biobanco de Navarrabiomed"
04/06/2024
Propuesta de adjudicación y adjudicación "Ayuda para la intensificación de personal F.E.A en Neurología para el Biobanco de Navarrabiomed"
Vídeo

La investigadora de Navarrabiomed Luisa Chocarro, reconocida entre los 111 jóvenes talentos a nivel nacional en el ámbito académico y de investigación

Luisa Chocarro, premiada por Nova Talent
Author
Navarrabiomed

•    El ranking lo publica la firma Nova Talent, que ha valorado un total de 1.500 candidaturas.



Nova Talent ha hecho público su clasificación anual de 111 mejores talentos menores de 35 años a nivel nacional. Entre los galardonados en la categoría de “Research & Academia” de este año se encuentra la investigadora predoctoral de la Unidad de Oncoinmunología de Navarrabiomed Luisa Chocarro

La edición 2024 ha contado con un total de 1.500 candidaturas dentro de las 11 categorías del certamen. El jurado, compuesto por expertos de todas las áreas, evaluó su trayectoria académica y profesional, así como sus habilidades personales y logros. También se tuvo en cuenta un test de razonamiento lógico, una entrevista y referencias. 

El acto de entrega de los reconocimientos se celebró el viernes, 24 de mayo en la sede de la IE University en Madrid. Los organizadores incidieron en la apuesta de los premios por destacar la trayectoria y potencial de los 111 jóvenes galardonados y se refirieron a ellos como los “líderes de hoy y del futuro” que tendrán un peso significativo en los avances de nuestra sociedad. 

Luisa Chocarro agradece a Nova Talent el reconocimiento recibido: “Supone un impulso para seguir aprendiendo y trabajando para el desarrollo de la ciencia”.


Trayectoria de Luisa Chocarro 

Luisa Chocarro, Pamplona 1996, estudió Bioquímica y Máster en Investigación, Desarrollo e Innovación de Medicamentos en la Universidad de Navarra. Actualmente está finalizando su tesis por la Universidad Pública de Navarra en Navarrabiomed, bajo la dirección de los doctores David Escors y Grazyna Kochan. 

Su trabajo doctoral se centra en estudiar los mecanismos de resistencia a la inmunoterapia contra el cáncer y desarrollar tratamientos novedosos para contrarrestarlos.

Categoría
Galería de imágenes
Luisa Chocarro Erauso.
Download Flecha que indica descarga
Acto de entrega de reconocimientos.
Download Flecha que indica descarga
Foto de familia con las 111 personas galardonadas.
Download Flecha que indica descarga
Documentación
Vídeo

Galectin-1 prevents pathological mechanisms involved in aortic stenosis

Represetación gráfica de la estenosis aórtica
Author
Navarrabiomed
  • Researchers from Navarrabiomed, CIBERCV in Spain and CONICET in Argentina have demonstrated that galectin-1 is a therapeutic target against aortic stenosis.
  • A new study, published in Faseb Journal, and with the participation of IIS-FJD-UAM researchers, suggests the regulation of galectin-1 expression by oestrogens as a possible differential mechanism in the development of valvular aortic stenosis between men and women.

Cardiovascular diseases are the leading cause of death and disability worldwide and represent increasing health expenditure due to the ageing of the population. Specifically, calcific aortic stenosis (CAS) is one of the most common forms of heart valve disease. Broadly speaking, CAS entails calcification and degeneration of the aortic valve, leading to the replacement of valve tissue with bone tissue and its narrowing. Opening of the aortic valve, and therefore the distribution of blood to the rest of the body, is compromised. 

There is currently no effective pharmacological treatment that alters the evolution of the disease, and aortic valve replacement is the only way to improve symptoms and long-term survival. The prevalence of CAS is estimated at around 3.4% in patients over 75 years of age, and increases notably with age. It is estimated that there are around 145,469 people with CAS in Spain, taking into account only the group of those over 75 years of age. As such, the identification of new mechanisms involved in this disease, as well as the search for new therapies to prevent mortality associated with these diseases, is a key research challenge.

In this field, a new study carried out by researchers from Navarrabiomed and the CIBER of Cardiovascular Diseases (CIBERCV) at the Health Research Institute of the Fundación Jiménez Díaz-Universidad Autonoma de Madrid (IIS-FJD-UAM), together with the Institute of Biology and Experimental Medicine (IBYME) of the National Council for Scientific and Technical Research (CONICET) in Buenos Aires, and published in Faseb Journal, has demonstrated the presence of galectin-1 in stenotic aortic valves, with the levels of this galectin being higher in the valves of men than in women. It should be noted that these differences suggest the need to develop sex-specific treatments, since the evolution, presentation and therapeutic response of the disease differs between sexes. All of this supports investment in research in order to improve current therapies. 

 

Galectin-1 levels are regulated by oestrogen in interstitial valve cells

Previous clinical studies showed that the valves of men and women are different, namely that women have a lower degree of calcification and greater valvular fibrosis than men.  In this sense, “elevated levels of galectin-1 may be related to the greater number of valvular interstitial cells (VICs) with an osteoblastic phenotype in the aortic valves of men,” comments Eva Jover, the lead author of the study.
With the intention of understanding the possible mechanisms underlying the findings in valve tissues from patients, the authors proposed to carry out studies with VICs in culture in the presence of oestrogen, the female sex hormone. “Interestingly, we were able to verify that oestrogens were only able to regulate the expression and secretion of galectin-1 in VICs from women, while they had no effect in those from men,” says Natalia López de Andrés. 

Treatment with galectin-1 prevents the development of valvular calcification

Previous studies by the CONICET and CIBER groups had demonstrated a cardioprotective and anti-inflammatory effect in experimental models of myocardial infarction and atherosclerosis. However, the effect of galectin-1 on the mechanisms involved in aortic stenosis was unknown. 
The study demonstrated that “treatment with galectin-1 was able to prevent inflammatory mediators and VIC calcification, which raises the possibility of evaluating the potential of this galectin as a possible therapeutic target in aortic stenosis,” says José Luis Martín Ventura.
However, “from a clinical point of view, further research is required to translate these findings to the patient, as well as the contribution of galectin-1 to the mechanisms involved in aortic stenosis,” concludes Gabriel Rabinovich.

Reference article:

Sex-dependent expression of galectin-1, a cardioprotective β-galactoside-binding lectin, in human calcific aortic stenosis.
Jover E, Martín-Núñez E, Garaikoetxea M, Matilla L, Blanco-Colio LM, Pérez-Sáez JM, Navarro A, Fernández-Celis A, Gainza A, Álvarez V, Sádaba R, Tamayo I, Rabinovich GA, Martín-Ventura JL, López-Andrés N. FASEB J. 2024 Feb 15;38(3):e23447. doi: 10.1096/fj.202301832RR

Categoría
Documentación
Vídeo

Navarrabiomed identifies a new therapeutic strategy that may allow molecular damage to be reversed in neurodegenerative diseases

Profesionales de Navarrabiomed y Universidad de Navarra que han participado en la investigación.
Author
Navarrabiomed
  • The study offers a new research approach, based on oncological therapies, that may slow down the progressive cognitive deterioration

The Navarrabiomed biomedical research centre has managed to establish an analytical strategy that allows the identification of drugs used in oncological therapies with significant potential to reverse the damage produced during the neurodegeneration process. The results of this study, which have been published in the leading journal in this field “Brain Pathology”, offer new therapeutic alternatives to treat neurodegenerative diseases such as Alzheimer’s, the leading cause of dementia, which currently affects 800,000 people in Spain, and will affect more than 16 million people in Europe by 2050. 

The study presented confirms that the treatment options available in neurodegenerative diseases are very limited and the economic investment to validate drugs is much lower than for therapeutic research carried out in other areas, for example oncology. In this sense, it proposes to use the abundant information available at a pharmacogenomic level in the field of oncology to identify possible therapeutic targets in neurodegenerative diseases such as Alzheimer’s disease.  

Professionals from the Clinical Neuroproteomics Unit at Navarrabiomed, directed by Dr. Enrique Santamaría, have led this study in which researchers from the Universidad de Navarra have also participated. 

 

Details of the research

Around 90% of patients with Alzheimer's disease lose their sense of smell several tears before the disease manifests clinically. In this research, the region of the olfactory tract from both subjects without a neurological disorder and with early-stage Alzheimer’s disease has been analysed at a proteomic level. This information, together with that generated by other international research groups in other brain regions of the olfactory axis, has led to the generation of a database containing extensive molecular information associated with the loss of smell in this disease. Using artificial intelligence-based workflows, researchers have compared this database with high-performance pharmacogenomic profiles, with the aim of identifying drugs (already used in clinical trials in oncology) that are able to reverse the molecular damage detected in the brain in Alzheimer’s disease. 

In this sense, a battery of drugs (specifically, antioxidant agents and kinase inhibitors) has been identified and are being analysed in depth in order to understand their ability to cross the blood-brain barrier, understand their mechanism of action in in vitro studies, as well as their impact at a cognitive level in animal models of Alzheimer’s disease. 

Dr. Santamaría indicates that “this systematic analysis of large-scale molecular data is aligned with the new paradigm in neurodegeneration, which considers some neurodegenerative diseases as proteinopenias rather than proteinopathies. With this approach, we aim to restore metabolism in a more global manner, unlike the latest therapies, which are aimed exclusively at reducing misfolded proteins in the brain and are not having the expected results.” 

Paz Cartas and Adriana Cortés, researchers at the Clinical Neuroproteomics Unit and the corresponding authors for the work, point out that “this type of methodological developments opens up many possibilities in drug testing in the field of neurology, since many of them have a low toxicity profile, and could be used intranasally in combination with current therapies, seeking synergistic effects that result in an improvement in the cognitive capacity of patients and therefore their quality of life.” This research has fostered new collaborations with different SNS-O Departments and other Spanish groups interested in increasing the translation of their lines of research towards innovative therapeutic approaches in other biomedical sectors. Dr. Santamaría points out that “we are currently using this strategy beyond Alzheimer’s disease, identifying drugs with possible therapeutic use in both Parkinson’s disease and Amyotrophic Lateral Sclerosis.”


Collaborations and funding 

The research forms part of the doctoral thesis of Paz Cartas, a researcher at the Clinical Neuroproteomics Unit, at the Universidad Pública de Navarra and has been carried out in close collaboration with Dr. Joaquín Fernández-Irigoyen, head of the Scientific-Technical Proteomics Department of Navarrabiomed and Drs. Maite Solas and Elena Puerta, researchers from the Department of Pharmacology and Toxicology of the Universidad de Navarra. 

It also forms part of INNOLFACT 2.0, a strategic project that has been financed by the Government of Navarra through the Call for Strategic Projects 2023–2026 and has the support of the Ministry of Science, Innovation and Universities, receiving institutional support from the Asociación de Familiares de Enfermos de Alzheimer de Navarra [Association of Families of Alzheimer’s patients of Navarra] (AFAN), the Asociación Navarra de Parkinson [Parkinson’s Association of Navarra] (ANAPAR,, Confederación Española de Alzheimer [Spanish Alzheimer’s Confederation] (CEAFA) and the Federación Española de Parkinson [Spanish Parkinson’s federation] (FEP).

The results of the study are part of the scientific activity of the Health Research Institute of Navarra (IdiSNA), a public-private group for the promotion of biomedical research in Navarra, to which both Navarrabiomed and the Universidad de Navarra belong.
 

Categoría
Galería de imágenes
De izda. a dcha.: Maite Solas y Elena Puerta (UN), Joaquín Fernández, Adriana Cortés, Paz Cartas, Enrique Santamaría, Elena Anaya y Mercedes Lachén (NB).
Download Flecha que indica descarga
Documentación
Vídeo

Lucía Lozano Vicario will defend her doctoral thesis on Friday 5th April

Lucía Lozano Vicario
Author
Navarrabiomed

Lozano, a predoctoral researcher from the Geriatrics and Active Ageing Unit (INGEA) at Navarrabiomed-IdiSNA and specialist in Geriatrics at the Hospital Universitario de Navarra, will defend her thesis from the Universidad Pública de Navarra on Friday, 5th April at 17:00 h, in the conference room at Navarrabiomed.

The doctoral study, entitled “Delirium in the elderly: from biomarkers to clinical practice”, has been carried out at Navarrabiomed and the Hospital Universitario de Navarra under the supervision of Drs. Mikel Izquierdo Redín, Principal Investigator of the Physical Exercise, Health and Quality of Life unit (E-FIT) at Navarrabiomed and Nicolás Martínez Velilla, Principal Investigator of the INGEA Unit. This project has also been possible thanks to support from the Scientific/Technical Proteomics Department and Biobank at Navarrabiomed.


Details of the research

This doctoral thesis concerns the potential use of biomarkers to predict the risk of delirium in older adults and the implementation of physical exercise as a tool to modify its evolution once established. Delirium is a severe and very common neuropsychiatric syndrome in the elderly that leads to disability and cognitive impairment. The underlying pathophysiological mechanisms are not well known and there is currently no effective treatment available for it. Serum biomarkers can be a minimally invasive and effective strategy to predict the onset of delirium, helping to better understand its pathophysiology and potentially contributing to its prevention, as well as the development of future therapeutic targets. In addition, physical exercise can offer an alternative to pharmacological treatment in a disease in which, to date, no medication has been proven to be effective.

This thesis is based on three studies carried out that have been published in different high-impact national and international journals (Q1-Q2) and a total of ten communications at international conferences. This research has led to the creation of new projects, such as the delirium working group of the Spanish Society of Geriatrics and Gerontology, where the doctoral student serves as secretary, and the delirium chapter of the Good Clinical Practice Guidelines in Geriatrics. A genetic study reveals how viruses that infect bacteria protect themselves and, at the same time, safeguard their hosts.
 

Categoría
Galería de imágenes
Lucía Lozano Vicario
Download Flecha que indica descarga
Documentación
Vídeo

A total of 4000 people will participate in a study that will allow us to understand why we get sick, improve prevention and move towards personalised precision medicine

Foto de familia representantes Cohorte IMPaCT Navarra
Author
Navarrabiomed

Salud has today presented, at the Lezkairu health centre, the national IMPaCT cohort project, which will run for 20 years


The regional Minister of Health, Fernando Domínguez, today chaired the presentation of the IMPaCT cohort study, which aims to carry out an exhaustive health study of 200,000 people representative of the Spanish population over the next 20 years (4000 in Navarra), to better understand the origin of the main diseases, thus helping to prevent and treat them and promoting personalised and precision medicine, at the Lezkairu health centre. Patricia Palacio and Óscar Lecea, principal investigator and collaborator of the study in Navarra, respectively, and the Primary Care manager Susana Miranda, also participated in the event.

The initiative is promoted nationally by the Instituto de Salud Carlos III, coordinated by the Centro de Investigación Biomédica en Red (CIBER), and 21 institutions and primary care services from all the Autonomous Communities and Cities are participating in it. In Navarra, IMPaCT cohort is managed by the Navarrabiomed biomedical research centre – Fundación Miguel Servet and, in turn, Primary Care of the Servicio Navarro de Salud – Osasunbidea coordinates and carries out the study, with the Lezkairu health centre as a node of the project. 


Randomised sample of 4000 people from 4 health centres

Over the next five years, 4000 people residing in Navarra aged between 16 and 79 years from four health centres are expected to join the study: Lezkairu, Segundo Ensanche, Milagrosa and Valle de Aranguren. To guarantee an accurate representation of the Spanish population, the participants are chosen at random, which why a person cannot volunteer to participate in IMPaCT cohort. 

At the beginning of their participation, and once every five years thereafter, they will undergo a complete physical examination at the Lezkairu health centre, answer a detailed health questionnaire, and have biological samples taken. Additionally, more frequent follow-up contacts will be made by phone or mobile applications. All this information will be complement that already available in the clinical or statistical databases of the SNS-O. 

As the Health Minister has emphasized, “the collaboration of citizens is essential. We are confident that the people contacted by Lezkairu understand the potential of the project, which will have an impact on improving the health of the entire population, and will participate if invited.” 
To date, the study has recruited ten people out of the 4000 that make up the randomized sample from Navarra. People selected by the SNS-O will receive a text message indicating that they will be contacted by the Lezkairu health centre to invite them to participate in the study and will be sent a link to the project’s information website where they can find all the details. The message will be addressed to “Health Communications” and will have the following text, both in its Spanish and Basque versions:

  • [Name + initials surnames]: We are carrying out a study on the health of the population of Navarra called IMPaCT cohort. We will call you from the Lezkairu health centre to invite you to participate. + information:  portalsalud.navarra.es/es/cohorte
  • [Izena + hasierako abizenak]: Nafarroako biztanleriaren osasunari buruzko azterlan bat egiten ari gara IMPaCT Kohortea. Lezkairuko Osasun Zentroak parte hartzera gonbidatzeko deituko dizu. Informazio +: portalsalud.navarra.es/eu/kohortea


Relevance of the research

The SNS-O Primary Care medical professionals Patricia Palacio and Óscar Lecea lead the research in Navarra and emphasize the importance of the study: “IMPaCT cohort will mark a before and after in the way biomedical research is carried out in Spain. The data obtained will allow the scientific community to better understand how to prevent the main diseases and deterioration associated with age, injuries and disability.”

The availability of a dynamic record of individual and population-based, clinical, genetic and epidemiological data and lifestyle habits, will allow the construction of predictive models of disease,the  identification of health inequalities, the monitoring of key indicators and evaluating the impact of health policies.

Successful examples can be found in other countries, such as the United Kingdom, France, Germany, Sweden or the USA. These cohorts have biological samples and very extensive epidemiological information - including social and economic factors - and constitute the basic tool for progress in prevention and personalised attention. As such, the IMPaCT cohort will allow a qualitative leap in research on precision medicine in Spain, thereby placing our country at the same level.
 

Categoría
Galería de imágenes
Profesionales de Atención Primaria, SNS-O y Navarrabiomed junto al consejero Fernando Domínguez.
Download Flecha que indica descarga
Rueda de prensa Cohorte IMPaCT Navarra
Download Flecha que indica descarga
La Investigadora Principal Patricia Palacio durante su intervención ante los medios.
Download Flecha que indica descarga
Mª Carmen, participante de Cohorte IMPaCT, durante las pruebas del estudio.
Download Flecha que indica descarga
El consejero ha participado en la realización de las pruebas a la participante.
Download Flecha que indica descarga
Rubén, participante de Cohorte IMPaCT, cumplimentando el consentimiento informado.
Download Flecha que indica descarga
Documentación
Vídeo
Presentación proyecto Cohorte IMPaCT
Presentación proyecto Cohorte IMPaCT

The European PreDisc project will help to generalise the prescription of personalised training for elderly patients during and after hospitalisation

Presentación proyecto PreDisc
Author
Navarrabiomed
  • Navarrabiomed, which leads this transnational cooperation project, presents the model applied in Navarra for the care of elderly hospitalised patients at the launch meeting for PreDisc.

The partners of the PreDisc project came together on Friday 15th March, at the Navarrabiomed biomedical research centre, to launch this transnational cooperation initiative between professionals from France, Portugal, Andorra and Spain, which is cofinanced with FEDER funds via the Sudoe program. The aim thereof is to prevent disability in elderly patients by promoting regular physical activity during and after periods of hospitalisation. 

The government of Navarra’s regional health minister, Fernando Domínguez, chaired the launch event for PreDisc, where he highlighted “the importance of implementing a personalised training program during hospitalisation and continuing it after discharge, with follow-up by Primary Care”. The project also includes a multicentre clinical trial to generate scientific evidence and promote the integration of such programs into standard clinical practice.

“Our society is undergoing changes, with more and more elderly people, with more chronic conditions and a greater likelihood of being admitted to hospital, therefore health systems, especially publicly funded ones, must adopt new practices to adapt to this new reality”, explained Domínguez.  Similarly, he indicated that “the solutions we can provide to the challenge of ageing are varied, but all point towards innovation as a working goal. Innovation in all its meanings: methodological, social, technological, etc. The PreDisc project is a good example of that”.

Furthermore, as the Minister of Health explained, “international cooperation, collaboration between research, hospital healthcare and Primary Care, the technological commitment, as well as the social and territorial orientation of the project have to generate an innovative model. of disability prevention in the elderly based on the individualised prescription and coordinated monitoring of a physical training program for them.” 

Together with representatives of the project’s partners, the head of Navarrabiomed, Maite Mendioroz Iriarte, the Managing Director of the Servicio Navarro de Salud-Osasunbidea, Alfredo Martinez Larrea, and the Managing Director of the Hospital Universitario de Navarra, Estrella Petrina Jáuregui, were also present.


The care model for hospitalised elderly patients in Navarra

After the institutional event, the attendees moved to the gym located in the HUN Geriatrics department, to learn about the care model for hospitalised elderly patients in Navarra and the impact that physical activity has during their stay in the hospital. 

The prescription of personalised physical activity during the hospitalisation period is being progressively integrated into the hospital system in order to prevent the functional deterioration associated with hospitalisation, although it has not yet been fully integrated into standard clinical practice. “The aim is to prioritise functional recovery, thanks to an individualised training program that allows the hospital stay to be shortened and avoids the disability that may arise during hospitalisation. This new care model allows a more comprehensive approach to elderly patients and moves us away from a model more focused on each patient's illness,” explains Nicolás Martínez Velilla, head of the Geriatrics and Active Ageing Unit (INGEA) of Navarrabiomed, head of the Geriatrics Department at HUN and principal investigator of the PreDisc project.

It must be remembered that the demographic situation of the countries in the SUDOE region (France, Spain, Andorra and Portugal), as is also the case for the rest of Europe, is characterized by a progressive ageing of the population, with a life expectancy of around 83–84 years. This phenomenon poses challenges in terms of healthcare and long-term care. To address these challenges, comprehensive strategies that promote active ageing, prevent disability, guarantee universal accessibility and adapt services to the needs of older people are needed. In this sense, geriatric care during the hospitalisation period is crucial in the life trajectory of these patients. 

In 2012, a prospective observational study was carried out in patients over 75 years of age admitted to the Geriatric Department of Navarra to evaluate the impact of bed rest on their functionality. It was found that 48.4% of patients suffered functional deterioration upon admission, with this persisting in 38.7% upon discharge. The average time spent in bed was 19.7 hours per day, and 58.1% were bedridden for an average of 20 hours per day. The length of time spent in bed was associated with functional deterioration and mortality, thus suggesting the need for interventions to improve patient care.

A randomized clinical trial conducted in 2019, also at HUN, investigated the impact of an individualised exercise intervention in very elderly people during acute hospitalisation. A total of 370 patients were randomly assigned to an exercise group or a control group. The main findings showed that the exercise group experienced significant improvements in functional capacity, cognitive status, mood, and quality of life compared to the control group. Furthermore, no adverse effects related to the exercise intervention were observed, thereby suggesting that it is safe and effective in reversing the functional decline related to acute hospitalisation in very elderly patients. 

To facilitate the integration of physical exercise during the hospitalisation period into standard clinical practice, it is necessary to generate greater scientific evidence through a multicentre clinical trial that will be carried out within the framework of the PreDisc project. In this case, the randomised, multicentre trial will be international and will include the participation of HUN, CHU Toulouse, Hospital Distrital da Figueira da Foz and Hospital Nuestra Señora de Meritxell in Andorra. Its objective is to generate greater scientific evidence and to be able to integrate personalised physical activity programs into standard clinical practice at the hospital level in the future. 

 

From the hospital to rural areas
In addition, to prevent longer-term disability and improve the quality of life of older people in their daily lives, the PreDisc project proposes to continue this physical exercise program started in the hospital after discharge, by way of follow-up in Primary Care and the development of an innovative eHealth tool.

And beyond patient care in the healthcare field, PreDisc also focuses its scope of action on the promotion of active ageing, especially in rural areas, through the development of technological tools, the training of healthcare personnel, carrying out home visits and events in rural communities, which should reduce unnecessary hospital admissions. 

PreDisc has a total budget of 1,288,550 euros, 75% of which is co-financed by the Interreg Sudoe Program, which supports regional development in south-western Europe by collaborating in the promotion of transnational projects through the European Regional Development Fund (FEDER). This program promotes cooperation to resolve problems common to the regions of southwestern Europe.

The project consortium is led by the Navarrabiomed biomedical research centre - Fundación Miguel Servet and includes the participation of the Navarra Health Research Institute (IdiSNA), Primary Care of the Servicio Navarro de Salud – Osasunbidea (SNS-O), the University of Deusto (Bizkaia, Euskadi), Center Hospitalier Universitaire de Toulouse Pôle Gériatrie (Occitania), Hospital Distrital da Figueira da Foz, EPE (Coimbra, Central Region) and Servei Andorrà d'Atenció Sanitària (Andorra), supported in turn by nine public and private organisations in southwestern Europe that participate as associate partners.
 

Categoría
Galería de imágenes
El consejero de Salud da la bienvenida a los socios del proyecto PreDisc
Download Flecha que indica descarga
Maite Mendioroz, directora de Navarrabiomed en la apertura del acto institucional de lanzamiento del proyecto
Download Flecha que indica descarga
Nicolás Martínez Vellila, IP del proyecto PreDisc
Download Flecha que indica descarga
El consejero de Salud y los socios de PreDisc visitan el gimnasio del servicio de Geriatría del HUN
Download Flecha que indica descarga
Fabiola Zambom, Investigadora posdoctoral de la Unidad Geriatría y Envejecimiento Activo (INGEA) de Navarrabiomed con un paciente, durante el programa de entrenamiento
Download Flecha que indica descarga
Sesión de entrenamiento en el gimnasio del servicio de Geriatría del HUN
Download Flecha que indica descarga
Documentación
Vídeo

Blanca Acha Santamaría will defend her doctoral thesis on Friday, 22nd March  

Blanca Acha Santamaría
Author
Navarrabiomed

Blanca Acha Santamaría, a predoctoral researcher from the NeuroEpigenetics Unit at Navarrabiomed-IdiSNA, will defend her thesis from the Universidad Pública de Navarra on Friday, 22nd March, at 11:30 h, in the conference room at Navarrabiomed. Her research, which is entitled “Identification epigenetic biomarkers for DNA methylation in peripheral blood from Alzheimer's disease patients” has been undertaken at Navarrabiomed under the supervision of Dr. Maite Mendioroz Iriarte, Principal Investigator, and Dr. Idoia Blanco Luquin, a postdoctoral researcher at the NeuroEpigenetics Unit at Navarrabiomed, as co-supervisor.


Research and results


The diagnosis of Alzheimer's disease (AD) is one of the main challenges faced by the scientific community. As such, epigenetics may be a novel source of of potential diagnostic biomarkers for this disease. This thesis is based on the findings of a previous study by the group, performed using samples from the hippocampus of AD patients, which found abnormalities in the DNA methylation pattern in regulatory regions related to neurogenesis. See the paper published in Clinical Epigenetics.


The main aim of the thesis was to find epigenetic biomarkers based on DNA methylation in peripheral blood from AD patients that may help the diagnosis, prognosis and treatment of this disease. The results highlight a potential role for DNA methylation as part of a panel of biomarkers to improve the diagnosis of AD and which is easy to apply and accessible to all patients.


Funding and publication of the research 


This project has been possible thanks to a grant from the Strategic Health Action, in the framework of the National Scientific Research, Development and Technological Innovation Plan, financed by the Instituto de Investigación Carlos III (ISCIII) as part of the Healthcare Research Fund (FIS) call for proposals 2018–2021 (FIS PI17/02218). A grant for hiring predoctoral researchers has also been provided by PFIS: contract for predoctoral training in healthcare-related research, funded by the Instituto de Investigación Carlos III (ISCIII) 2019–2022 (FI18/00150).


The results of the research in this doctoral thesis have been published in the journal Neurology, “Association of Blood-based DNA Methylation Markers With Late-Onset Alzheimer Disease”. Moreover, Blanca Acha has presented scientific communications at several national and international conferences.

Categoría
Galería de imágenes
Blanca Acha Santamaría
Download Flecha que indica descarga
Documentación
Vídeo

Los primeros pasos en la vacuna contra la alergia al cacahuete prometen "buena tolerancia y seguridad”

alergia cacahuete
Author
Navarrabiomed
  • La Clínica Universidad de Navarra y el Hospital Universitario de Navarra siguen buscando candidatos para probar este avance contra la alergia alimentaria más letal, una investigación que dirigen las doctoras Marta Ferrer y Ana Tabar
     


Las alergias alimentarias condicionan la vida de más de 220 millones de personas en todo el mundo. Entre ellas, la alergia al cacahuete es una de las más comunes y de las más mortales. Solo en España, afecta a 200.000 personas. A pesar de la prevalencia, todavía no existe ninguna medicación que la combata y el único tratamiento desensibilizante no tiene un efecto definitivo, porque ofrece, de momento, una tolerancia temporal.

La Clínica Universidad de Navarra y el Hospital Universitario de Navarra tienen puesto en marcha desde 2020 un ensayo clínico de la primera inmunoterapia dirigida a tratar la alergia a este fruto seco. La doctora Marta Ferrer, especialista del Departamento de Alergología de la Clínica, explica que “hasta ahora se ha administrado INP20 a 32 pacientes alérgicos al cacahuete, y los resultados son prometedores en cuanto a su buena tolerancia y seguridad”.

Este innovador tratamiento está compuesto por nanopartículas que contienen cacahuete. Gracias a su tamaño, consiguen llegar hasta las células T, un tipo de células inmunitarias, y regular su activación. Así, el sistema inmunitario no reconoce como extraña la sustancia de este fruto seco, hasta convertirse en tolerable para el organismo humano. Los resultados del ensayo se presentarán a finales de febrero en el congreso anual de la Academia Americana de Alergia, Asma e Inmunología en Washington.

La vacuna ha sido desarrollada por la empresa biotecnológica navarra InnoUp Farma. Maite Agüeros, su directora general, destaca que “a diferencia de otras estrategias de inmunoterapia, nuestra tecnología permite que no se active la respuesta inmune que causa anafilaxia y otras reacciones graves”.

Este ensayo clínico, coordinado por la doctora Marta Ferrer y la doctora Ana Tabar, directora del Servicio de Alergología del Hospital Universitario de Navarra, es el resultado del trabajo del grupo de investigación 'Alergias, nuevas formas de inmunoterapia y bases inmunológicas', del Instituto de Investigación Sanitaria de Navarra (IdiSNA). “La búsqueda de una inmunoterapia contra la alergia al cacahuete está en la primera línea de investigación de nuestra especialidad. Si resulta definitivamente efectiva, esta vacuna permitirá desarrollar otras para revertir diferentes alergias alimentarias”, concluye la doctora Tabar.
 

Proceso de reclutamiento abierto

El ensayo clínico, de fase I y II, se está llevando a cabo tanto en la Clínica Universidad de Navarra -en sus sedes de Pamplona y Madrid-, como en el Hospital Universitario de Navarra. Las personas interesadas en participar pueden contactar con el Departamento de Alergología de la Clínica (ensayocacahuete@unav.es – 948 25 54 00) o del Hospital Universitario de Navarra (servicio.alergias@navarra.es – 848 42 86 68).

Categoría
Documentación
Vídeo